X
KEY PRODUCTS KEY SERVICES
https://pharmaceuticalmanufacturer.media/pharmaceutical-industry-insights/latest-pharmaceutical-manufacturing-industry-insights/zambon-and-ima-active-paving-the-way-towards-process-optimis/
https://www.prnewswire.com/news-releases/zambon-to-attend-the-chest-annual-meeting-2022-301649239.html
https://www.prnewswire.com/news-releases/zambon-announces-attendance-at-american-thoracic-society-ats-2022-annual-meeting-301545971.html
https://www.prnewswire.com/news-releases/zambon-to-present-data-on-lung-transplantation-trends-and-survival-rates-in-europe-at-ishlt-2022-301532746.html
https://www.zambon.com/en/media/press/2022-04-21-zambon-receives-us-fda-breakthrough-therapy-designation-cms-i-nebr-patients
https://www.ouest-france.fr/pays-de-la-loire/avrille-49240/pres-d-angers-greve-chez-zach-system-a-avrille-l-usine-classee-seveso-7b48f9c6-9e2b-11ec-816b-ed6ee69963f0
https://www.zambon.com/en/media/press/2022-02-21-covid-19-probiotic-formula-reduces-symptom-duration-and-viral-load-increases
https://www.zambon.com/en/media/press/2021-09-08-positive-results-phase-3-promis-i-study-cms-i-nebr-patients-non-cystic
https://www.zambon.com/en/media/press/2021-05-12-newron-and-zambon-sign-agreement-potentially-pivotal-study-safinamide
https://www.zambon.com/sites/corporate/files/press/files/2021-04/press-release-world-pd-day_synapses_eng.pdf
Market Place
Share 
